MMS Wins Best Global Biotech CRO in the International Life Sciences Awards 2018
UNITED KINGDOM (August 23, 2018) – MMS Holdings Inc. (MMS) – an award-winning, global clinical research organization – announced today that it has won the award for Best Global Biotech CRO in the International Life Sciences Awards 2018 by Global Health & Pharma (GHP) magazine.
Now in its third consecutive year, the prestigious International Life Sciences Awards highlights the scientific, technological and business development of healthcare across all areas.
“This award is made possible by the hundreds of colleagues and sponsors that work together tirelessly to develop life-changing therapies for patients globally,” said Lisa James, Director, Business Operations & Client Relations, MMS. “We proudly accept this award, and take it as a challenge to continue to reinvent ourselves and our processes to provide best-in-class service every time.”
Discussing the success of their winners, Heather Ryan, Awards Coordinator, GHP, commented: “The Life Sciences sector is constantly evolving and innovating, and the individuals, teams and companies leading this drive forward deserve recognition. As such, these awards celebrate the dedication and passion shown for the industry. I am proud of all of my winners and look forward to seeing further success from them over the years to come.”
GHP prides itself on the validity of its awards and winners. The awards are given solely on merit and are awarded to commend those most deserving for their ingenuity and hard work, distinguishing them from their competitors and proving them worthy of recognition.
To gain insight into the working practices of the “best of the best” in the health and pharma industries, please visit: https://www.ghp-news.com/2018-international-life-sciences-awards-2018
About MMS
MMS is an award-winning global clinical research organization (CRO) that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex regulatory submission challenges. As a data-focused CRO, we are pioneers and leaders in regulatory submissions for our sponsors. Strong industry experience and a data-driven approach to drug development make MMS a valuable partner in creating compelling submissions that meet rigorous regulatory standards. For more information, visit www.mmsholdings.com.
About GHP
GHP is a quarterly magazine brought to you by AI Global Media Ltd, a publishing house that has reinvigorated corporate finance news and reporting. Its topical news articles make it a valued read, and this readability ensures that advertisers will benefit greatly from their investment.
Established to enhance communication networks & collaboration across all themes and disciplines within 3 main categories; Human, Animal & Environmental Health.
Media contact
Avery Zimmerman
media@mmsholdings.com
Suggested For You
news
December 8th, 2021
MMS Holdings Wins 2021 Scrip Award for Best Contract Research Organization
news
October 28th, 2021
Praxis bioresearch seeks support from MMS for Alzheimers Disease Therapeutics
news
September 22nd, 2021
MMS SmartStart™ Tech-Enabled Solution Eases Document Content Creation Process
news
October 28th, 2020
MMS Academy Launches Mobile App for Accessing Pharmaceutical Industry Virtual Learning Courses from Anywhere
news
August 18th, 2020
MMS Academy Partners with MPGI in India
news
October 10th, 2019
MMS Holdings Announces Status As A Finalist For Best Contract Research Organization
news
June 27th, 2019
MMS Holdings Launches New Time-Saving Application to Automatically Perform Quality Control and Style Checks for Medical Writers
news
March 13th, 2019
GHP Recognises MMS Holdings in the 2019 Biotechnology Awards Winners
news
May 1st, 2018
MMS Partners with University of Findlay to Provide Medical Writing and Clinical Trial Disclosure Courses
news
November 15th, 2017
MMS Selected by Paratek to Support its NDA Submissions for Omadacycline
news
June 11th, 2014
MMS partners with Wayne State University to place Graduate Students in Scientific Summer Internship Program
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance